There are numerous studies that have showed that the expression and enzymatic activities of all the three SOD isotypes are at a significant decrease across the majority types of cancers: CuZnSOD (SOD1) activity is decreased in breast carcinoma [146], gastric adenocarcinoma [147], and hepatocarcinogenesis [148] and MnSOD (SOD2) expression is downregulated in the ductal carcinoma tissues in patients with breast cancer [149] and skin cancers [150] and displays low levels which correlates with pancreatic cancerous tumor growth [151] and other primary ovarian and prostate tumors [152]. The gene discussed is SOD2; the disease is breast carcinoma.